S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Celsius Holdings Faces Class Action Over Alani Nu Marketing Practices

A federal class action lawsuit now targets Celsius Holdings, alleging the company misled investors regarding the health risks of its Alani Nu energy drinks. The litigation centers on claims that the firm knowingly marketed high-caffeine products to teenagers despite public assurances that it avoided that demographic.

Celsius Holdings Faces Class Action Over Alani Nu Marketing Practices
Photo: Bio & News

The complaint filed by Robbins LLP focuses on a period between February 21, 2025, and June 3, 2026. Plaintiffs argue that Celsius failed to disclose significant cardiac risks associated with the drinks, which contain 200 milligrams of caffeine—double the daily recommended limit for individuals aged 12 to 17. The legal action follows a wrongful death suit involving a Texas teenager, which triggered an investigation by Texas Attorney General Ken Paxton into potential violations of state trade practice laws.

Market volatility followed these revelations. Celsius shares dropped 4.18% on April 10, 2026, after reports surfaced regarding the wrongful death case. A sharper decline of 7.53% occurred on June 4, 2026, following the announcement of the Attorney General's investigation. Investors who suffered losses during the class period are eligible to participate in the litigation, with a lead plaintiff deadline set for November 3, 2026. Robbins LLP is representing investors on a contingency fee basis.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!